Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2 but not CALR mutation.

Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Mara De Amici, Carlotta Abbà, Gianluca Viarengo, Laura Villani, Robert P Gale, Vittorio Rosti, Margherita Massa

Journal: Leukemia research 2020;90():106319

PMID: 32081398

Full Text on Elsevier Science View on PubMed

Abstract

Address: Center for the Study of Myelofibrosis, Laboratory of Biochemistry-Biotechnology and Advanced Diagnosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy. Electronic address: [email protected].; Center for the Study of Myelofibrosis, Laboratory of Biochemistry-Biotechnology and Advanced Diagnosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Laboratory of Immuno-Allergology of Clinical Chemistry and Pediatric Clinic, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Laboratory of Biochemistry-Biotechnology and Advanced Diagnosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Immunohematology and Transfusion Service, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College, London, UK.

DOI: 10.1016/j.leukres.2020.106319

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-33

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CALR-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Alleles, Amino Acid Substitution, Biomarkers, Calreticulin, Disease Progression, Humans, Interleukin-2 Receptor alpha Subunit, Janus Kinase 2, Mutation, Primary Myelofibrosis